Risk factors
Phathom Pharmaceuticals (PHAT) risk factors
Item 1A of every Phathom Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors92 risks29 new26 dropped30 reworded
Phathom Pharmaceuticals faces intense competition, reliance on VOQUEZNA commercial success, and strict ongoing regulatory requirements following product launches.
Filed Feb 26, 2026 - FY2024 10-K risk factors89 risks
Phathom Pharmaceuticals faces significant financial risks driven by heavy reliance on vonoprazan products like VOQUEZNA, substantial operating losses, and a reliance on third-party manufacturers.
Filed Mar 06, 2025